Thinking About Changing from Mounjaro to Ozempic? Read This First

Why is Ozempic not the right switch target for weight loss?

Ozempic (semaglutide 0.5mg, 1mg, 2mg) holds a UK marketing authorisation specifically for glycaemic control in adults with type 2 diabetes. It is not licensed as a weight-management medicine, and the NHS medicines page for semaglutide makes this distinction clearly. Prescribing Ozempic off-label for weight loss is a separate clinical decision that carries different obligations for any prescriber — it is not a routine alternative to Wegovy.

Wegovy is the correct semaglutide product for weight management. It is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure or dyslipidaemia. The active molecule is the same (semaglutide) but the licensed indication, approved dosing pathway and regulatory position are different. That distinction is not a technicality; it affects what a prescriber can responsibly offer you.

So if you are currently on Mounjaro for weight management and wondering about switching, the honest comparison to make is Mounjaro versus Wegovy, not Mounjaro versus Ozempic. If you want to understand whether you can change from Mounjaro to Ozempic and what that actually involves clinically, we cover that question directly. Our page on changing from Mounjaro to Wegovy covers that question in full.

How do Mounjaro and Ozempic actually differ as medicines?

Both medicines are injectable GLP-1 receptor agonists given once weekly, but they work through different mechanisms. Mounjaro (tirzepatide) activates two gut-hormone receptors (GLP-1 and GIP) making it the only dual-agonist weight-management medicine currently licensed in the UK. Ozempic activates the GLP-1 receptor only, the same single pathway as Wegovy.

The table below compares key facts. The weight-loss figures are included for context from their respective clinical trials and NICE appraisals; Ozempic's results in people without diabetes are not the basis of its UK licence.

The side-effect profiles are broadly similar across both medicines because both activate the GLP-1 pathway: nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported effects, typically most noticeable when starting or when the dose steps up. A fuller look at how the two licensed weight-management medicines compare sits on our Wegovy vs Mounjaro page.

Can a prescriber switch you from Mounjaro to Ozempic for weight loss?

In principle, a prescriber can prescribe any licensed medicine off-label if they judge it clinically appropriate and document their reasoning. In practice, for weight management, most prescribers would reach for Wegovy rather than Ozempic because Wegovy carries the weight-loss licence, the NICE recommendation, the trials in people without diabetes, and the dosing pathway designed specifically for that population.

There is no clinical scenario where Ozempic is the obvious first choice over Wegovy for someone whose goal is weight management. If cost is the driver, it is worth knowing that the licensed semaglutide weight-loss product in the UK is Wegovy, and any legitimate comparison of costs should be like-for-like on licensed, clinically supervised treatment. Our page on Wegovy vs Mounjaro cost covers what the price difference actually means in practice.

If you have type 2 diabetes and weight management is a secondary goal, the picture changes, and that is precisely the kind of situation where a clinician's judgment is indispensable. Questions our prescribers hear regularly include whether a switch makes sense given someone's diabetes control, their current dose, and how long they have been on treatment. Timing matters too: a switch mid-titration, or just before a holiday when you need stable supply, requires more planning than a switch at a maintenance dose on a quiet month.

For a detailed look at the evidence on moving between these medicines, our page on changing from semaglutide to tirzepatide works through the clinical considerations from the other direction.

What are the licensed weight-loss options available in the UK?

For adults seeking clinician-supervised weight management, the two injectable medicines licensed in the UK are Mounjaro (tirzepatide) and Wegovy (semaglutide injection). Both are prescription-only and require a clinical assessment before a prescriber can issue a prescription. The NHS England page on weight management injections describes both medicines and the NHS access pathways for each.

As of summer 2026, the Wegovy tablet (oral semaglutide, 25mg maintenance dose) is also licensed in the UK for weight management, the first oral GLP-1 medicine with that authorisation. That gives adults who prefer not to inject a third clinician-prescribed option. None of these three options is available without a valid prescription following clinical review.

At nume, our GPhC-registered pharmacy (premises registration 9012878, verifiable on the GPhC register) dispenses Mounjaro and Wegovy for weight management. Every consultation is read personally by a prescriber (not processed by software) and treatment is only issued when the clinical picture supports it. If you would like to explore your options, including whether Wegovy might be the appropriate switch from Mounjaro in your case, people who have already made that move share their experiences on our Mounjaro to Wegovy reviews page, and our free consultation page is the place to start. Which medicine suits you is a decision our prescribers make with you, based on your full history.